Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension
Emily Lau, Elizabeth Liu, Samantha M. Paniagua, Amy Sarma, Giovanna A. Zampierollo, Begoña López, Javier Dı́ez, Thomas J. Wang, Jennifer E. Ho
Abstract
We investigated the effect of galectin-3 (Gal-3) inhibition with modified citrus pectin on markers of collagen metabolism in a proof-of-concept randomized placebo-controlled trial of participants with elevated Gal-3 levels and hypertension. Although higher Gal-3 levels were associated with female sex, diabetes, and reduced glomerular filtration rate in cross-sectional analyses, treatment with modified citrus pectin did not change collagen markers. The effect of Gal-3 inhibition among individuals with heart failure warrants further investigation.
Topics & Concepts
Galectin-3PectinPlaceboDiabetes mellitusInternal medicineRenal functionMedicineHeart failureEndocrinologyCardiologyUrologyChemistryBiochemistryPathologyAlternative medicineGalectins and Cancer BiologyCardiovascular, Neuropeptides, and Oxidative Stress ResearchSignaling Pathways in Disease